Search results
2 new COVID variants called 'FLiRT' are spreading in the U.S. What are the symptoms?
TODAY via Yahoo News· 2 days agoThe new "FLiRT" COVID-19 variants, including KP.2, are spreading in the United States. Will there be...
HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update
WFRV 5 Green Bay· 6 days agoDelivered solid performance to start 2024, with record-breaking first quarter revenue of 34.1 billion KRW. Phase 3 VELOS-4 study of tanfanercept in dry eye disease expected ...
...-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on...
The Yuma Sun· 3 days agoTarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and continued favorable safety profile.KSI-501 clinical and non-clinical ...
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...
GuruFocus.com via Yahoo Finance· 3 days agoRevenue: Grew 7% year-over-year to $3.1 billion, excluding COVID antibodies contributions. Net Income: First quarter diluted net income per share was $9.55. Free Cash Flow: Generated $1.< ...
CDC says bird flu viruses "pose pandemic potential," cites major knowledge gaps
WINK TV Southwest Florida· 1 day agoBird flu continues to appear to pose a “low risk to the general public” for now, the Centers for...
Labcorp gains FDA approval for hemophilia B diagnostic test By Investing.com
Investing.com· 4 days agoLabcorp (NYSE: LH) has announced the FDA approval of its nAbCyte Anti-AAVRh74var HB-FE Assay, a...
FDA Issues Final Rule on Laboratory-Developed Tests | JD Supra
JD Supra· 4 days agoOn April 29, 2023, the FDA announced a final rule on regulation of laboratory developed tests (LDTs). The rule explicitly categorizes in vitro...
Realising the potential of correlates of protection for vaccine development, licensure and use:...
Nature· 7 days agoVaccine development, particularly late-stage development is costly, time-consuming and is associated with high risk of candidate failure, with as few as 10% of vaccine candidates achieving licensure ...
... III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for...
WFRV 5 Green Bay· 3 days agoHanAll has initiated a Phase III VELOS-4 study to evaluate the efficacy and safety of tanfanercept in dry eye based on the findings from the previous Phase III VELOS-3 study ...
Taking the bite out of snake venom
Phys.org· 6 days agoEvery year around 5.4 million people globally—often in the world's poorest communities—are bitten by venomous snakes, with countries such as Bangladesh,...